Compare Crispr Therapeutics AG (CRSP) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Riot Platforms Inc — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Riot Platforms Inc trades at $20.32 (market cap $7.59B). The key difference: Riot Platforms Inc is the larger of the two by market cap, and Riot Platforms Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | RIOT | |
|---|---|---|
Market Cap | $5.23B | $7.59B |
Sector | Health | Technology |
52-Week High | $76.78 | $28.67 |
52-Week Low | $44.34 | $11.33 |
Enterprise Value | $3.65B | $8.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
RIOT Platforms trades at $20.32, up 4.74% today, amid strong technical resistance near $21-$23 levels. The stock shows bearish momentum despite recent positive news about a $9.1 billion AI infrastructure deal with Anthropic. Fundamentally, the company continues to post significant losses with a -196.28% net income margin, though revenue growth remains steady at $675 million projected for 2026.
While analyst consensus remains overwhelmingly bullish with a $33.40 price target, investors face substantial execution risks as RIOT transitions from bitcoin mining to AI infrastructure. The company's persistent negative cash flow and high valuation multiples present challenges despite the transformative potential of the Anthropic partnership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
